All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: EB613
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The Phase 2 clinical trial of EB613 is a dose-ranging, placebo-controlled study in postmenopausal female subjects with osteoporosis, or low bone mineral density (BMD), and is being conducted at four leading medical centers in Israel.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegloticase,Mycophenolate Mofetil
Therapeutic Area: Musculoskeletal Product Name: Krystexxa
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Reducing Immunogenicity of Pegloticase demonstrated that 86.4 percent of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL through Month 3, the primary endpoint of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegloticase,Mycophenolate Mofetil
Therapeutic Area: Musculoskeletal Product Name: Krystexxa
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Additional studies on the concomitant use of KRYSTEXXA (pegloticase injection) with an immunomodulator to optimize the treatment for people living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) will also be presented.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Fulcrum will present four posters on its integrated approach to the evaluation of FSHD patients, highlighting the progress made in the development of imaging and molecular biomarkers in FSHD and the design of clinical trials of losmapimod in FSHD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Aptinyx has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMC-1
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 25, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMC-1
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 28, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UBX0101
Therapeutic Area: Musculoskeletal Product Name: UBX0101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
There was no statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline in WOMAC-A, an established measurement of pain in OA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Losmapimod
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Results from the interim analysis in the first 29 randomized subjects indicate that DUX4-driven gene expression did not show a separation from placebo at 16 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: EB613
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Entera's intend to move EB613 development program into a Phase 2b or Phase 3 pivotal clinical trial.